TCBP Historical Balance Sheet

TCBP Stock

USD 0.37 0.05 15.94%

Trend analysis of TC BioPharm Holdings balance sheet accounts such as Total Stockholder Equity of 3.2 M, Other Liab of 3.1 M, Property Plant And Equipment Net of 3.2 M or Accounts Payable of 1.2 M provides information on TC BioPharm's total assets, liabilities, and equity, which is the actual value of TC BioPharm Holdings to its prevalent stockholders. By breaking down trends over time using TC BioPharm balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining TC BioPharm Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether TC BioPharm Holdings is a good buy for the upcoming year.

TC BioPharm Inventory

(1.49 Million)

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TC BioPharm Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

About TCBP Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of TC BioPharm Holdings at a specified time, usually calculated after every quarter, six months, or one year. TC BioPharm Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of TC BioPharm and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which TCBP currently owns. An asset can also be divided into two categories, current and non-current.

TC BioPharm Balance Sheet Chart

At this time, TC BioPharm's Common Stock Shares Outstanding is relatively stable compared to the past year. As of 02/01/2025, Capital Lease Obligations is likely to grow to about 2.1 M, while Net Tangible Assets are likely to drop (546.9 K).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of TC BioPharm assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in TC BioPharm Holdings books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on TC BioPharm balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of TC BioPharm Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from TC BioPharm's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into TC BioPharm Holdings current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TC BioPharm Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	2.5M	1.8M	1.6M	1.5M
Total Assets	11.3M	8.9M	10.3M	10.0M

Short Long Term Debt Total Total Assets

TC BioPharm balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.45	-0.3	-0.35	0.48	0.29	0.55	0.18	-0.18	-0.5	0.18	-0.2	0.31	0.17	-0.44	0.31	0.49	-0.05	0.13	0.05	-0.54	0.46	0.24	-0.29	0.42	-0.04
Short Long Term Debt Total	-0.45		0.58	0.82	-0.94	-0.2	-0.99	-0.01	0.33	0.96	-0.11	0.1	-0.14	-0.01	0.68	-0.14	-0.09	-0.3	0.01	0.17	0.11	-0.48	-0.22	0.91	-0.81	0.13
Other Current Liab	-0.3	0.58		0.92	-0.38	-0.8	-0.54	-0.67	-0.46	0.35	-0.75	0.47	0.63	-0.67	0.92	0.63	-0.7	0.27	-0.71	-0.55	0.71	-0.48	0.42	0.41	-0.15	-0.54
Total Current Liabilities	-0.35	0.82	0.92		-0.63	-0.63	-0.78	-0.49	-0.2	0.66	-0.59	0.41	0.35	-0.49	0.92	0.35	-0.51	0.14	-0.51	-0.32	0.52	-0.39	0.28	0.67	-0.4	-0.4
Total Stockholder Equity	0.48	-0.94	-0.38	-0.63		-0.07	0.96	-0.27	-0.6	-0.96	-0.19	0.2	0.36	-0.28	-0.45	0.36	-0.13	0.57	-0.29	-0.45	0.09	0.62	0.54	-0.95	0.96	-0.38
Other Liab	0.29	-0.2	-0.8	-0.63	-0.07		0.16	0.97	0.81	0.04	0.96	-0.85	-0.78	0.96	-0.85	-0.78	0.94	-0.68	0.96	0.91	-0.93	0.14	-0.74	0.14	-0.32	0.67
Net Tangible Assets	0.55	-0.99	-0.54	-0.78	0.96	0.16		-0.03	-0.4	-0.97	0.06	-0.06	0.23	-0.03	-0.64	0.23	0.1	0.32	-0.06	-0.22	-0.13	0.53	0.31	-0.91	0.85	-0.16
Property Plant And Equipment Net	0.18	-0.01	-0.67	-0.49	-0.27	0.97	-0.03		0.9	0.2	0.98	-0.9	-0.78	1.0	-0.73	-0.78	0.93	-0.84	0.99	0.98	-0.91	-0.09	-0.87	0.32	-0.52	0.76
Current Deferred Revenue	-0.18	0.33	-0.46	-0.2	-0.6	0.81	-0.4	0.9		0.55	0.88	-0.75	-0.87	0.91	-0.44	-0.87	0.74	-0.85	0.93	0.96	-0.71	-0.3	-0.95	0.57	-0.8	0.78
Net Debt	-0.5	0.96	0.35	0.66	-0.96	0.04	-0.97	0.2	0.55		0.11	-0.05	-0.42	0.2	0.48	-0.42	0.08	-0.4	0.23	0.38	-0.05	-0.41	-0.41	0.92	-0.89	0.27
Retained Earnings	0.18	-0.11	-0.75	-0.59	-0.19	0.96	0.06	0.98	0.88	0.11		-0.87	-0.78	0.98	-0.79	-0.78	0.89	-0.81	0.99	0.94	-0.89	-0.07	-0.87	0.2	-0.45	0.77
Accounts Payable	-0.2	0.1	0.47	0.41	0.2	-0.85	-0.06	-0.9	-0.75	-0.05	-0.87		0.56	-0.9	0.67	0.56	-0.79	0.83	-0.84	-0.88	0.76	0.3	0.81	-0.29	0.43	-0.61
Cash	0.31	-0.14	0.63	0.35	0.36	-0.78	0.23	-0.78	-0.87	-0.42	-0.78	0.56		-0.78	0.52	1.0	-0.6	0.51	-0.83	-0.82	0.58	-0.06	0.76	-0.31	0.54	-0.59
Non Current Assets Total	0.17	-0.01	-0.67	-0.49	-0.28	0.96	-0.03	1.0	0.91	0.2	0.98	-0.9	-0.78		-0.72	-0.78	0.92	-0.85	0.99	0.98	-0.91	-0.11	-0.88	0.32	-0.53	0.78
Non Currrent Assets Other	-0.44	0.68	0.92	0.92	-0.45	-0.85	-0.64	-0.73	-0.44	0.48	-0.79	0.67	0.52	-0.72		0.52	-0.74	0.36	-0.72	-0.59	0.75	-0.34	0.45	0.4	-0.18	-0.45
Cash And Short Term Investments	0.31	-0.14	0.63	0.35	0.36	-0.78	0.23	-0.78	-0.87	-0.42	-0.78	0.56	1.0	-0.78	0.52		-0.6	0.51	-0.83	-0.82	0.58	-0.06	0.76	-0.31	0.54	-0.59
Net Receivables	0.49	-0.09	-0.7	-0.51	-0.13	0.94	0.1	0.93	0.74	0.08	0.89	-0.79	-0.6	0.92	-0.74	-0.6		-0.74	0.91	0.87	-1.0	0.13	-0.65	0.23	-0.35	0.7
Common Stock Shares Outstanding	-0.05	-0.3	0.27	0.14	0.57	-0.68	0.32	-0.84	-0.85	-0.4	-0.81	0.83	0.51	-0.85	0.36	0.51	-0.74		-0.82	-0.88	0.7	0.57	0.91	-0.57	0.76	-0.83
Non Current Liabilities Total	0.13	0.01	-0.71	-0.51	-0.29	0.96	-0.06	0.99	0.93	0.23	0.99	-0.84	-0.83	0.99	-0.72	-0.83	0.91	-0.82		0.97	-0.9	-0.07	-0.88	0.3	-0.54	0.81
Capital Lease Obligations	0.05	0.17	-0.55	-0.32	-0.45	0.91	-0.22	0.98	0.96	0.38	0.94	-0.88	-0.82	0.98	-0.59	-0.82	0.87	-0.88	0.97		-0.85	-0.2	-0.91	0.49	-0.67	0.77
Inventory	-0.54	0.11	0.71	0.52	0.09	-0.93	-0.13	-0.91	-0.71	-0.05	-0.89	0.76	0.58	-0.91	0.75	0.58	-1.0	0.7	-0.9	-0.85		-0.18	0.62	-0.19	0.31	-0.67
Other Current Assets	0.46	-0.48	-0.48	-0.39	0.62	0.14	0.53	-0.09	-0.3	-0.41	-0.07	0.3	-0.06	-0.11	-0.34	-0.06	0.13	0.57	-0.07	-0.2	-0.18		0.5	-0.52	0.63	-0.33
Other Stockholder Equity	0.24	-0.22	0.42	0.28	0.54	-0.74	0.31	-0.87	-0.95	-0.41	-0.87	0.81	0.76	-0.88	0.45	0.76	-0.65	0.91	-0.88	-0.91	0.62	0.5		-0.46	0.75	-0.84
Total Liab	-0.29	0.91	0.41	0.67	-0.95	0.14	-0.91	0.32	0.57	0.92	0.2	-0.29	-0.31	0.32	0.4	-0.31	0.23	-0.57	0.3	0.49	-0.19	-0.52	-0.46		-0.91	0.27
Net Invested Capital	0.42	-0.81	-0.15	-0.4	0.96	-0.32	0.85	-0.52	-0.8	-0.89	-0.45	0.43	0.54	-0.53	-0.18	0.54	-0.35	0.76	-0.54	-0.67	0.31	0.63	0.75	-0.91		-0.58
Property Plant And Equipment Gross	-0.04	0.13	-0.54	-0.4	-0.38	0.67	-0.16	0.76	0.78	0.27	0.77	-0.61	-0.59	0.78	-0.45	-0.59	0.7	-0.83	0.81	0.77	-0.67	-0.33	-0.84	0.27	-0.58

Click cells to compare fundamentals

TC BioPharm Account Relationship Matchups

TC BioPharm balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	7.3M	8.0M	11.3M	8.9M	10.3M	10.0M
Short Long Term Debt Total	2.6M	15.9M	2.5M	1.8M	1.6M	1.5M
Other Current Liab	3.1M	9.6M	7.3M	2.5M	2.8M	5.1M
Total Current Liabilities	4.2M	20.6M	9.2M	4.8M	5.5M	9.4M
Total Stockholder Equity	(3.3M)	(16.6M)	331.3K	2.7M	3.1M	3.2M
Property Plant And Equipment Net	4.6M	3.7M	3.3M	2.6M	2.4M	3.2M
Net Debt	1.8M	14.3M	(2.4M)	(661.5K)	(595.3K)	(565.5K)
Retained Earnings	(19.9M)	(33.5M)	(33.4M)	(38.8M)	(35.0M)	(36.7M)
Accounts Payable	638.4K	1.4M	882.4K	1.8M	2.1M	1.2M
Cash	748.0K	1.6M	4.8M	2.5M	2.8M	2.3M
Non Current Assets Total	5.0M	4.2M	3.8M	3.2M	2.9M	3.6M
Cash And Short Term Investments	748.0K	1.6M	4.8M	2.5M	2.8M	2.3M
Net Receivables	1.2M	1.5M	1.8M	1.2M	1.1M	1.4M
Common Stock Shares Outstanding	11.2M	7.8M	13.7M	123.6M	142.1M	149.2M
Liabilities And Stockholders Equity	7.3M	8.0M	11.3M	8.9M	10.3M	10.0M
Non Current Liabilities Total	6.4M	4.0M	1.8M	1.5M	1.3M	1.3M
Capital Lease Obligations	3.0M	2.9M	2.1M	1.8M	1.6M	2.1M
Inventory	(1.2M)	(1.5M)	(1.8M)	(1.2M)	(1.4M)	(1.5M)
Other Current Assets	230.7K	811.3K	836.1K	4.1M	4.7M	4.9M
Other Stockholder Equity	(1.6M)	16.7M	33.7M	41.5M	47.7M	50.1M
Total Liab	10.6M	24.6M	11.0M	6.2M	5.6M	10.4M
Net Invested Capital	(3.3M)	(9.8M)	627.8K	2.7M	3.1M	3.2M
Property Plant And Equipment Gross	6.9M	6.7M	6.5M	6.8M	6.1M	5.4M
Total Current Assets	2.2M	3.9M	7.4M	5.7M	6.6M	5.2M
Capital Stock	1.8M	195.5K	397.5K	2.1K	1.9K	1.8K
Net Working Capital	(2.0M)	(16.7M)	(1.7M)	950.3K	1.1M	1.1M
Short Term Debt	442.7K	7.6M	981.5K	305.3K	351.1K	333.6K
Intangible Assets	423.8K	483.6K	553.0K	615.2K	707.4K	523.9K
Common Stock	194.6K	195.5K	397.5K	2.1K	1.9K	1.8K

Pair Trading with TC BioPharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with TCBP Stock

0.77	JNJ	Johnson Johnson	Pair Corr
0.7	LLY	Eli Lilly Earnings Call This Week	Pair Corr

Moving against TCBP Stock

0.73	BMY	Bristol Myers Squibb Earnings Call This Week	Pair Corr
0.61	EHAB	Enhabit	Pair Corr
0.51	ALTS	ALT5 Sigma Symbol Change	Pair Corr
0.49	LFCR	Lifecore Biomedical	Pair Corr
0.39	GILD	Gilead Sciences Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.

The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for TCBP Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

TCBP Historical Balance Sheet

TC BioPharm Inventory

(1.49 Million)

About TCBP Balance Sheet Analysis

TC BioPharm Balance Sheet Chart

Total Assets

Total Current Liabilities

TC BioPharm balance sheet Correlations

TC BioPharm Account Relationship Matchups

High Positive Relationship

High Negative Relationship

TC BioPharm balance sheet Accounts

Pair Trading with TC BioPharm

Moving together with TCBP Stock

Moving against TCBP Stock

Additional Tools for TCBP Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 0.99	Property Plant And Equipment Net
Non Current Liabilities Total	+ 0.99	Retained Earnings
Non Current Liabilities Total	+ 0.99	Non Current Assets Total
Retained Earnings	+ 0.98	Property Plant And Equipment Net

Inventory	- 1.0	Net Receivables
Net Tangible Assets	- 0.99	Short Long Term Debt Total
Net Debt	- 0.97	Net Tangible Assets
Net Debt	- 0.96	Total Stockholder Equity
Other Stockholder Equity	- 0.95	Current Deferred Revenue
Total Liab	- 0.95	Total Stockholder Equity